Cognition Therapeutics Secures Composition of Matter Patent for Zervimesine Through 2045
CGTX sits 57% above its 52-week low of $0.55.
Summary
Cognition Therapeutics received a U.S. composition of matter patent for a novel crystalline form of zervimesine (CT1812), its lead drug candidate, extending protection to 2045 with a possible five-year extension. The patent covers the polymorph, its production process, and therapeutic methods for Alzheimer's, dry AMD, and DLB. The company also disclosed an FDA meeting next week to finalize endpoint selection for its registrational DLB program, with manufacturing of the new form planned for Q1 2027. This strengthens the IP position around a pivotal Phase 3 program and signals near-term regulatory progress.
At the time of this announcement, CGTX was trading at $0.87 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $81.5M. The 52-week trading range was $0.55 to $2.05. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: GlobeNewswire.